Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb 13;146(2):657-667.
doi: 10.1093/brain/awac276.

Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis

Affiliations
Case Reports

Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis

Felix Gövert et al. Brain. .

Abstract

Autoimmune encephalitis can be classified into antibody-defined subtypes, which can manifest with immunotherapy-responsive movement disorders sometimes mimicking non-inflammatory aetiologies. In the elderly, anti-LGI1 and contactin associated protein like 2 (CASPR2) antibody-associated diseases compose a relevant fraction of autoimmune encephalitis. Patients with LGI1 autoantibodies are known to present with limbic encephalitis and additionally faciobrachial dystonic seizures may occur. However, the clinical spectrum of CASPR2 autoantibody-associated disorders is more diverse including limbic encephalitis, Morvan's syndrome, peripheral nerve hyperexcitability syndrome, ataxia, pain and sleep disorders. Reports on unusual, sometimes isolated and immunotherapy-responsive movement disorders in CASPR2 autoantibody-associated syndromes have caused substantial concern regarding necessity of autoantibody testing in patients with movement disorders. Therefore, we aimed to systematically assess their prevalence and manifestation in patients with CASPR2 autoimmunity. This international, retrospective cohort study included patients with CASPR2 autoimmunity from participating expert centres in Europe. Patients with ataxia and/or movement disorders were analysed in detail using questionnaires and video recordings. We recruited a comparator group with anti-LGI1 encephalitis from the GENERATE network. Characteristics were compared according to serostatus. We identified 164 patients with CASPR2 autoantibodies. Of these, 149 (90.8%) had only CASPR2 and 15 (9.1%) both CASPR2 and LGI1 autoantibodies. Compared to 105 patients with LGI1 encephalitis, patients with CASPR2 autoantibodies more often had movement disorders and/or ataxia (35.6 versus 3.8%; P < 0.001). This was evident in all subgroups: ataxia 22.6 versus 0.0%, myoclonus 14.6 versus 0.0%, tremor 11.0 versus 1.9%, or combinations thereof 9.8 versus 0.0% (all P < 0.001). The small group of patients double-positive for LGI1/CASPR2 autoantibodies (15/164) significantly more frequently had myoclonus, tremor, 'mixed movement disorders', Morvan's syndrome and underlying tumours. We observed distinct movement disorders in CASPR2 autoimmunity (14.6%): episodic ataxia (6.7%), paroxysmal orthostatic segmental myoclonus of the legs (3.7%) and continuous segmental spinal myoclonus (4.3%). These occurred together with further associated symptoms or signs suggestive of CASPR2 autoimmunity. However, 2/164 patients (1.2%) had isolated segmental spinal myoclonus. Movement disorders and ataxia are highly prevalent in CASPR2 autoimmunity. Paroxysmal orthostatic segmental myoclonus of the legs is a novel albeit rare manifestation. Further distinct movement disorders include isolated and combined segmental spinal myoclonus and autoimmune episodic ataxia.

Keywords: CASPR2; autoimmune encephalitis; movement disorders; myoclonus; neuronal autoantibodies.

PubMed Disclaimer

Similar articles

Cited by

  • Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
    Greguletz P, Plötz M, Baade-Büttner C, Bien CG, Eisenhut K, Geis C, Handreka R, Klausewitz J, Körtvelyessy P, Kovac S, Kraft A, Lewerenz J, Malter M, Nagel M, von Podewils F, Prüß H, Rada A, Rau J, Rauer S, Rößling R, Seifert-Held T, Siebenbrodt K, Sühs KW, Tauber SC, Thaler F, Wagner J, Wickel J, Leypoldt F, Rittner HL, Sommer C, Villmann C, Doppler K; GENERATE study group. Greguletz P, et al. J Neurol. 2024 May;271(5):2736-2744. doi: 10.1007/s00415-024-12224-4. Epub 2024 Feb 22. J Neurol. 2024. PMID: 38386048 Free PMC article.
  • [Additional functional symptoms in Parkinson's disease and tremor syndromes].
    Zeuner KE, Schwingenschuh P. Zeuner KE, et al. Nervenarzt. 2024 Jun;95(6):525-531. doi: 10.1007/s00115-023-01594-1. Epub 2024 Jan 5. Nervenarzt. 2024. PMID: 38180511 German.
  • Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
    Campetella L, Smolik K, Farina A, Joubert B, Muñiz-Castrillo S, Desestret V, Honnorat J. Campetella L, et al. J Neurol. 2025 Apr 24;272(5):359. doi: 10.1007/s00415-025-13094-0. J Neurol. 2025. PMID: 40274643 Free PMC article. Review.
  • Recent advances in autoimmune encephalitis.
    Ferreira JHF, Disserol CCD, de Freitas Dias B, Marques AC, Cardoso MD, Silva PVC, Toso FF, Dutra LA. Ferreira JHF, et al. Arq Neuropsiquiatr. 2024 Dec;82(12):1-13. doi: 10.1055/s-0044-1793933. Epub 2024 Dec 20. Arq Neuropsiquiatr. 2024. PMID: 39706227 Free PMC article. Review.
  • Movement disorders in autoimmune encephalitis: an update.
    Qin M, Chen J, Guo X, Xiang X, Nie L, Wang Y, Mao L. Qin M, et al. J Neurol. 2023 Nov;270(11):5288-5302. doi: 10.1007/s00415-023-11881-1. Epub 2023 Jul 31. J Neurol. 2023. PMID: 37523063 Review.

Publication types

Substances

Supplementary concepts